Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 19

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 19
---
 certain of its affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment,
hedging, financing and brokerage activities. The Placement Agent and certain of its affiliates have, from time to time, performed, and
may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which
they received or will receive customary fees and expenses.

In
the ordinary course of their various business activities, the Placement Agent and certain of its affiliates may make or hold a broad array
of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank
loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments issued by us and our affiliates. If the Placement Agent or its affiliates have a lending relationship with us, they
routinely hedge their credit exposure to us consistent with their customary risk management policies. The Placement Agent and its affiliates
may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the creation of short
positions in our securities or the securities of our affiliates, including potentially the Common Stock offered hereby. Any such short
positions could adversely affect future trading prices of the Common Stock offered hereby. The Placement Agent and certain of its affiliates
may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments.

<div align='center'>S-12

LEGAL MATTERS</div>

The validity of the securities
offered hereby will be passed upon by Sichenzia Ross Ference Carmel LLP. Lowenstein Sandler LLP, New York, New York, is acting as counsel
for the Placement Agent in connection with this offering.

<div align='center'>EXPERTS</div>

The consolidated financial
statements of INmune Bio Inc. as of and for the years ended December 31, 2024 and 2023 appearing in INmune Bio Inc.’s Annual Report
on Form 10-K for the year ended December 31, 2024 have been audited by Marcum LLP, as set forth in its report thereon, which includes
an explanatory paragraph as to the